Daito Pharmaceutical Co.,Ltd. (TYO:4577)

Market Cap	42.84B +36.7%
Revenue (ttm)	51.20B +8.1%
Net Income	2.23B -15.8%
EPS	74.32 -13.5%
Shares Out	29.16M
PE Ratio	19.77
Forward PE	18.42
Dividend	40.00 (2.72%)
Ex-Dividend Date	May 28, 2026

Volume	73,900
Average Volume	97,555
Open	1,464.00
Previous Close	1,464.00
Day's Range	1,457.00 - 1,475.00
52-Week Range	970.00 - 1,521.00
Beta	0.28
RSI	53.79
Earnings Date	Apr 17, 2026

About Daito Pharmaceutical

Daito Pharmaceutical Co.,Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. It offers active pharmaceutical ingredients for generic drugs; develops and manufactures generic and over-the-counter drugs; and contract manufacturing services for ethical drugs. The company is also involved in the wholesale of pharmaceutical and veterinary medicine. It exports its products to the United States, as well as European and Asian countries. The company was formerly known as Daito Corporation and changed its nam...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1942
• Employees: 1,073
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4577

Financial Performance

In fiscal year 2025, Daito Pharmaceutical's revenue was 50.64 billion, an increase of 7.99% compared to the previous year's 46.90 billion. Earnings were 1.91 billion, a decrease of -42.09%.